RAB6A and cancer: Cancer-specific or cancer-enriched targets in this concern are still rare, but there is a high variety of lysosomal proteins, e.g., Rab GTPases, ion channels, lipases or the V-ATPase, which could serve as specific targets to disturb lysosomal function and thus drug resistance phenotypes of cancer cells more selectively.